Adherex Technologies Inc. Announces Corporate Goals For 2006

RESEARCH TRIANGLE PARK, N.C.--(BUSINESS WIRE)--Jan. 11, 2006--Adherex Technologies Inc. (TSX:AHX)(AMEX:ADH), a biopharmaceutical company with a broad portfolio of oncology products under development, today announced its corporate goals for 2006. "2005 was a year in which Adherex achieved many important milestones, including the completion of the first Phase I trial of ADH-1, initiation of two additional Phase Ib/II trials in the U.S. and Europe, the launch of the first Phase II trial of ADH-1, and the in-license and rapid return of eniluracil to the clinic," said William P. Peters, M.D., Ph.D., Chairman and CEO of Adherex. "2006 will be an even more important and active year for Adherex, as we continue to aggressively move our drugs forward in their clinical development. Ultimately, shareholder value will be driven by the results of our clinical and laboratory studies. To that end, we expect our 2006 clinical program to yield a significant amount of safety and response data on both ADH-1 and eniluracil, which will help define the optimal disease settings, dose and schedule required for subsequent Phase III trials. We will also continue to emphasize our preclinical efforts to develop the scope and depth of our cadherin biotechnology platform by advancing the development of our small molecule N-cadherin antagonists as well as other molecules which affect the function of cadherins."